Shopping Cart
- Remove All
- Your shopping cart is currently empty
Abeprazan (DWP14012) is a potassium-competitive acid blocker developed as a potential alternative to proton pump inhibitors for treating acid-related diseases. It inhibits H+, K+-ATPase through reversible potassium-competitive ionic binding, without requiring acid activation [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | Abeprazan (DWP14012) is a potassium-competitive acid blocker developed as a potential alternative to proton pump inhibitors for treating acid-related diseases. It inhibits H+, K+-ATPase through reversible potassium-competitive ionic binding, without requiring acid activation [1]. |
In vitro | The mechanism of action of Abeprazan involves reversible binding to H+, K+-ATPase. Unlike PPIs, it does not require an acidic environment for activation [1]. |
In vivo | In various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models[1], DWP14012 inhibited acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion was equal to or greater than that of vonoprazan, a previously approved P-CAB. |
Alias | DWP14012 |
Molecular Weight | 410.41 |
Formula | C19H17F3N2O3S |
Cas No. | 1902954-60-2 |
Relative Density. | 1.35 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.